Yayin da nake aiki kan tsarin rigakafi, na gano da gangan wani sabon nau'in tantanin halitta wanda ke kashe yawancin ciwon daji. Sabuwar ci gaban na iya zama babbar fa'ida ga masu ciwon daji, kamar yadda sabon t-cell da aka gano yana kashe yawancin ƙwayoyin cutar kansa yadda ya kamata. Koyaya, an iyakance wannan ga dakunan gwaje-gwaje har zuwa yanzu, kuma ana buƙatar ƙarin bincike na dogon lokaci don haɓaka cikakkiyar magani.
Masana kimiyyar Burtaniya daga Jami'ar Kiwon Lafiya ta Cardiff sun gano wani nau'in tantanin halitta (T-cell) da gangan da ke lalata yawancin nau'ikan cutar kansa. Kamar yadda a cikin Telegraph wannan na iya zama babban ci gaba da aka gano a cikin farautar maganin ciwon daji na kowane nau'in ciwon daji. Likitan, yayin da yake nazarin kwayoyin jinin jini a cikin bankin jini, ya gano wani sabon nau'in t-cell wanda ke ɗauke da sabon mai karɓa wanda aka riga aka gani wanda yake aiki kamar ƙugiya mai ɗaurewa, yana kama da yawancin cututtukan daji na ɗan adam, yayin da yake yin watsi da ƙwayoyin lafiya. Jaridar Telegraph ta ruwaito. A cikin yanayin dakin gwaje-gwaje, ƙwayoyin rigakafi sanye take da sabon mai karɓa, sun sami damar kashe ƙwayoyin cutar kansa daga gabobin da yawa, gami da huhu, jini, ƙasusuwa, da koda.
A cewar Farfesa Andrew Sewell, shugaban binciken, kuma kwararre kan kwayar halitta a Jami'ar Kiwon Lafiya ta Cardiff, Ana iya amfani da wannan binciken don ƙirƙirar magani na duniya don yawancin cututtukan daji.
Ciwon daji yana da'awar kewaye 10 miliyan yana rayuwa a kowace shekara a duniya, kuma rabon Indiya yana da ƙima 8% na haka. Waɗannan lambobin suna da ban tsoro kuma suna ƙaruwa kowace shekara tare da sabbin hanyoyin da fasaha don gano farkon cutar kansa.
The WHO data shows India has around 1.2 million new cases each year, and more than 50% of these cases will be diagnosed in women. Ciwon daji na nono has gone up by more than 39% between 1990 and 2016 and is the most common cancer among women. The Lancet report goes on to add that between 1990 and 2016, the number of cancer deaths in India increased by 112 percent. At the same time, the incidence of cancer cases also increased by 48.7 percent. The report also highlights that in 2016, the country had 67,000 lung cancer patients, of which 72.2 percent were men, and ciwon daji also increased by 32.2 percent since 1990, with 30,000 cases reported in 2016.
Sabon bincike akan maganin kansa
A kan kowace irin kamuwa da cuta, tsarin rigakafi na jiki yana fara aiki kuma yana aiki azaman kariya ta dabi'a a kansa. Duk da haka, yana kuma kai hari ga kwayoyin cutar kansa. Masana kimiyya a Jami'ar Kiwon Lafiya ta Cardiff, Biritaniya, suna neman hanyoyin da ba a saba da su ba da kuma hanyoyin da ba a gano ba tsarin rigakafi ya kai hari ga ciwace-ciwacen daji. An gano cewa akwai t-cell da ke kai hari tare da kashe yawancin nau'ikan kwayoyin cutar daji.
Ta yaya wannan t-cell ke aiki don warkar da ciwon daji?
A team at Cardiff Medical University, Britain, discovered a T-cell and its receptor that could find and kill a wide range of cancerous cells in the lab, including lung cancer, skin cancer, blood cancer, colon cancer, breast cancer, ciwon daji na kashi, prostate cancer, ovarian cancer, kidney cancer, and cervical cancer cells. Exactly how does this happens is yet to be explored and scientists are working on it.
Wannan takamaiman mai karɓar T-cell yana hulɗa tare da kwayar zarra da ake kira MR1, wanda ke saman kowace sel a cikin jikin mutum.
Kuna so karanta: Motar T-cell far a Indiya
Ana tunanin cewa MR1 yana nuna gurɓataccen ƙwayar cuta da ke gudana a cikin kwayar cutar kansa zuwa tsarin rigakafi.
"Mu ne farkon wanda ya bayyana wani T-cell wanda ke gano MR1 a cikin kwayoyin cutar kansa-wanda ba a yi ba a baya, wannan shine irinsa na farko," in ji wani ɗan bincike Garry Dolton. BBC.
Menene sauran masana suka ce game da gano cutar kansa?
Lucia Mori da Gennaro De Libero, daga Jami'ar Basel a Switzerland, sun ce binciken yana da "babbar dama" amma kuma a farkon lokacin da za a ce zai yi aiki a duk cutar kansa.
"Mun yi matukar farin ciki game da ayyukan rigakafin wannan sabuwar T-cell da kuma yiwuwar amfani da TCRs din su a cikin tasirin cutar kwaro," in ji su.
Daniel Davis, farfesa a fannin ilimin rigakafi a Jami'ar Manchester, ya ce: "A yanzu, wannan bincike ne na asali kuma ba kusa da ainihin magungunan marasa lafiya ba.
"Babu wata tambaya cewa gano abu ne mai ban sha'awa, duka don ciyar da ilimin mu game da tsarin rigakafi da kuma yiwuwar sababbin magunguna nan gaba."
Kuna so karanta: CAR T Cell far in China
